Description
Ticlopidine-d4 is intended for use as an internal standard for the quantification of ticlopidine (Item No. 20770) by GC- or LC-MS. Ticlopidine is a thienopyridine P2Y12 receptor antagonist.1 It inhibits aggregation of human platelets induced by collagen, arachidonic acid (Item No. 90010), and ADP (Item No. 16778; IC50s = 75, 600, and 1,300 μM, respectively).2 It also inhibits ADP-induced aggregation of rat platelets and decreases thrombus weight in vivo in a rat model of arterio-venous shunt thrombosis when administered at a dose of 100 mg/kg.3 Ticlopidine (300 mg/kg) inhibits healing of acetic acid-induced gastric ulcers in rats.4 Formulations containing ticlopidine have been used in the prevention of thrombotic stroke.WARNING This product is not for human or veterinary use.
References
[1] ITALO PORTO. Platelet P2Y12 receptor inhibition by thienopyridines: status and future.[J]. Expert opinion on investigational drugs, 2009, 18 9: 1317-1332. DOI:
10.1517/13543780903176415[2] BRUNO J J. The mechanisms of action of ticlopidine[J]. Thrombosis research, 1983, 29: Pages 59-67. DOI:
10.1016/0049-3848(83)90359-6[3] ATSUHIRO SUGIDACHI. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties[J]. British Journal of Pharmacology, 2009, 129 7: 1439-1446. DOI:
10.1038/sj.bjp.0703237[4] LI MA. Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release[J]. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98 1: 6470-6475. DOI:
10.1073/pnas.111150798
